News
Forus gains AI backing with 21 per cent stake

Eye-screening firm Forus Health has received a 21 per cent investment to scale its AI diagnostics across India and abroad.
Forus Health develops ophthalmic diagnostics — tools that detect eye disease — and “oculomics”, which uses eye images to flag wider risks such as diabetes or hypertension. Its devices have screened over 22 million people in more than 75 countries, and its AI-integrated platform has delivered comprehensive eye assessments to over five million patients.
The deal is a secondary transaction intended to support the scale-up of Forus Health’s AI eye-screening platforms and international deployment.
Inviga Healthcare Fund has acquired the 21 per cent stake, its second major investment after Mynvax in 2024, signalling support for India-built AI diagnostics in global markets.
Dr B. S. Ajaikumar, founder of Inviga Healthcare Fund and chair of HCG, said: “Forus Health embodies the Inviga ethos: clinically strong, technologically deep, socially impactful, growth oriented, profitable. This investment is a testament to our confidence in India’s ability to produce world-class healthcare innovations for domestic and international markets. We are delighted to partner with visionary founders like Chandrasekhar (KC) who combine deep insight with execution to make preventive, equitable healthcare a reality.”
K. Chandrasekhar, founder and chief executive of Forus Health, said: “We are thrilled to welcome Inviga as we enter the next phase of our growth. Their expertise in healthcare, operational experience, and insights from a clinician’s perspective are incredibly valuable. Together, we aim to enhance our AI and platform capabilities, utilise our proven ability to innovate in medical devices, and expand our reach both in India and globally. Our mission remains focused on eradicating preventable blindness.”
Rakshith Rangarajan, fund manager at Inviga Healthcare Fund, said: “Our collaboration with Forus is a strategic step intended to facilitate the expansion of a reputed med-tech franchise that is serving a significant market demand through a sustainable and economically sound business model. It reflects our commitment to advancing accessible solutions that address large, unsolved health challenges. The Make in India, Make for India and Make for the World ethos of Forus resonates deeply with our Fund. We’re confident this partnership will drive sustained growth and long-term value creation.”
The burden underscores the need for scalable tools: an estimated 270 million people in India live with visual impairment, much of it preventable; globally, 2.2bn people live with vision impairment or blindness, with over 1bn cases considered preventable or treatable. Forus Health’s 3nethra screening devices and wearable 3nethra specto — a smartphone-operated digital refractor for remote and tele-optometry — target earlier detection and easier access to care.
News
Don’t miss you essential monthly agetech update

Your essential monthly update on agetech’s progress
Welcome to your monthly snapshot of the facts, figures, opinions, trends and challenges shaping the development of agetech.
Our new monthly tracker report aims to provide an concise update for busy agetech professionals on the many factors influencing your work.
Here you will find a concise breakdown of deals, developments and opportunities from the last 30 days; and insight and opinion from leading thinkers in the field.
We hope you find something useful and/or inspiring below – and welcome any feedback about what else you’d like to see included.
News
One in 20 children has high blood pressure, study finds

Rates of high blood pressure in children have almost doubled since 2000, with more than one in 20 now affected, new global research shows.
In 2020, 6.2 per cent of under-19s had high blood pressure, compared with 3.2 per cent in 2000.
High blood pressure, also known as hypertension, now affects 114 million children worldwide, according to an international team including academics from the University of Edinburgh and Zhejiang University in China.
The authors examined data on 443,000 children from 21 countries and found obesity was a substantial driver of the problem.
Nearly 19 per cent of children and adolescents with obesity have high blood pressure, compared with 3 per cent among those with a healthy weight.
In England, one in ten (10.5 per cent) children in the first year of primary school is obese. By the final year, 22.2 per cent are obese, according to the National Child Measurement Programme.
High blood pressure occurs when the force of blood pushing against artery walls is consistently too high, which can damage blood vessels and organs over time.
Co-author Dr Peige Song of Zhejiang University attributed higher rates to unhealthy diets, decreased physical activity and rising childhood obesity.
She said: “The analysis showed that children and adolescents with obesity are nearly eight times more likely to develop hypertension.”
“Parents play a pivotal role in preventing and managing high blood pressure in children.
“Promoting healthy habits, such as a balanced diet rich in fruits, vegetables and whole grains while minimising salt and sugar intake, can substantially reduce the risk of hypertension.”
News
US$100m UK tech entrepreneurs shift focus from real estate to longevity

Whilst running a US$100m-a-year technology business Paul Statham and his team turned their attention to longevity.
Speaking to Agetech World the London-based entrepreneur took up the story: “ I travel extensively and the only way I could keep in touch with my late mother Kathy, who was suffering from dementia, was through the telephone.
“But an hour’s phone call is not the same for someone who wants people around her more of the time, that resonated with me and so we decided to look at the problem and find a solution.”
This led to the foundation of the home-based technology smart speaker Sentai, which provides domestic companionship and assistance for those of advancing years.
Back in 2021 the Sentai team secured £172,568 from quango Innovate UK and Statham and his team have since invested ‘several million pounds’ of their own money bringing Sentai to fruition.
What is Sentai?
Statham elaborated: “Sentai is a smart speaker which uses AI to communicate and support older adults in their daily tasks. It acts as a digital companion as well as a digital assistant.

Paul Statham
“In the assistant space it will provide daily reminders of tasks and appointments, and from the companion perspective, it will engage in conversation.
“The AI technology available now is truly phenomenal; unbelievably clever. It is able to get to know the person it is talking to and truly does become part of their world.
“Sentai is there to support and help people; it doesn’t take over their lives but works as part of their life. It gets to know people and can play games, deliver medical reminders, or, for example, assist with reminder prompts on things such as ensuring their drinking enough water or getting enough exercise.
“As we age, we need more care, but many elderly people are becoming isolated and spending less time with their families, so we came up with the idea of using this technology to help provide additional support.”
What is the potential of Sentai?
Trials of the first Sentai began over the summer with the company looking to launch in January 2026.
It has a number of primary target markets in its sights with the potential to save taxpayers and home care organisations many millions of pounds.
Statham continued: “There’s the retail/consumer market. We’re selling Sentai through the internet, and other primary marketing channels.
“Then there’s the domiciliary care market; companies and organisations who provide home care for people.
“Sentai is a great help to these organisations and they are potentially prime users of the product as it allows them to provide additional hours of coverage with slimmed-down costs.
“In the UK it’s difficult to find domestic care workers, there are not enough as it is, and demand is set to increase. So the domiciliary care market is a massive opportunity and we are really leaning into this.”
Sentai is working with a number of local authorities delivering home care and it is also currently involved in a trial with an NHS Trust in South East which permits two-way communications between a patient and the hospital.
“When patients leave hospital, if they’ve not got a loved one or a family member to stay with them, then they will take a Sentai home. This will allow the hospital to assess their progress and make sure their needs are being met.
“We’ve got various councils piloting Sentai for assisted living in trials which allow the care providers to monitor a patient’s needs with the view of developing Sentai as a concierge service.”
While some trial users have been found to use Sentai more than expected others have been less verbose, and, so, over time the AI speaker is able to familiarise itself with its user’s personalities and deliver ‘concise’ or ‘chatty’ modes depending on individual preferences.
At £29.50 (US’$39) per month, or £294 (US$387) annually for use of the speaker and app, Sentai’s pricing makes the technology relatively accessible.

Keeping families connected
Statham and his team founded their previous company Condeco Software twenty years ago.
It had developed into a leading global player in workspace management and resource scheduling, effectively ensuring the real estate footprint of a company matched its needs.
As the pandemic shifted workspace requirements Condeco’s software made it one of the leading players in its field.
By late 2022, as the company’s annual revenues topped US$100m, it was sold in a private equity deal for an undisclosed sum, with some of this money now being ploughed into Sentai.
Statham added: “We launched our product because we were thinking of our own loved ones and how we wanted to stay in contact with them.
“That is the DNA of the business. We want to keep families connected and keep older adults relevant and help them live independently for longer.
“If we can help with loneliness and companionship, and help connect families to their loved ones, then that will be an unbelievable success.”
News2 months agoNHS warns against dismissing symptoms as ‘natural part of ageing’
News4 weeks agoNewLimit raises US$45m for epigenetic longevity drugs
Wellness2 weeks agoEngineered ‘young’ immune cells could help to reverse Alzheimer’s damage
Insights1 month agoWeight loss jabs should be first-line obesity treatment in most cases, new guidance states
Wellness3 weeks agoCzech firm approved for hydrogen Alzheimer’s trial
News3 days agoUS$100m UK tech entrepreneurs shift focus from real estate to longevity
News1 month agoNew drug enhances GLP-1 weight loss without extra added effects, trial finds
News3 weeks agoCreativity helps keep the brain young, study finds




















